Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Hypertension Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/hr.2010.205PMID 21107327
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Candesartan effect on inflammation in hypertension

  2010cited by this paper
• Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients

  2010cited by this paper
• Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity.

  2010cited by this paper
• Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current status

  2010cited by this paper
• Chronic Treatment With Losartan Results in Sufficient Serum Levels of the Metabolite EXP3179 for PPAR&ggr; Activation

  2009cited by this paper
• The evolving story of the RAAS in hypertension, diabetes and CV disease – moving from macrovascular to microvascular targets

  2009cited by this paper
• The role of inflammation on atherosclerosis, intermediate and clinical cardiovascular endpoints in type 2 diabetes mellitus.

  2009cited by this paper
• Emerging concepts in the pathophysiology of type 2 diabetes mellitus.

  2009cited by this paper
• Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.

  2009cited by this paper
• Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE

  2009cited by this paper
• 2007 ESH/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept

  2009cited by this paper
• Endothelial dysfunction in normal and abnormal glucose metabolism.

  2008cited by this paper
• Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia.

  2008cited by this paper
• Angiotensin II induces matrix metalloproteinase-9 expression via a nuclear factor-kappaB-dependent pathway in vascular smooth muscle cells.

  2008cited by this paper
• Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure.

  2008cited by this paper
• Losartan Elevates the Serum High-Molecular Weight—Adiponectin Isoform and Concurrently Improves Insulin Sensitivity in Patients with Impaired Glucose Metabolism

  2008cited by this paper
• Molecular characteristics of serum visfatin and differential detection by immunoassays.

  2007cited by this paper
• Effects of Telmisartan and Losartan on Insulin Resistance in Hypertensive Patients with Metabolic Syndrome

  2007cited by this paper
• Retinol binding protein-4 levels and clinical features of type 2 diabetes patients.

  2007cited by this paper
• Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity.

  2007cited by this paper
• Effect of acute hyperinsulinaemia with and without angiotensin II type 1 receptor blockade on resistin and adiponectin concentrations and expressions in healthy subjects.

  2007cited by this paper
• Plasma Retinol-Binding Protein-4 Concentrations Are Elevated in Human Subjects With Impaired Glucose Tolerance and Type 2 Diabetes

  2007cited by this paper
• Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome

  2007cited by this paper
• Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects.

  2007cited by this paper
• Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?

  2007cited by this paper
• Metabolic actions of angiotensin receptor antagonists: PPAR-γ agonist actions or a class effect?

  2007cited by this paper
• The CNS renin-angiotensin system

  2006cited by this paper
• C-reactive protein (CRP)-lowering agents.

  2006cited by this paper
• Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.

  2006cited by this paper
• Neuroendocrine and metabolic effects of adipocyte-derived hormones.

  2006cited by this paper
• Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity.

  2005cited by this paper
• Resistin Is an Inflammatory Marker of Atherosclerosis in Humans

  2005cited by this paper
• Adiponectin: a relevant player in PPARγ-agonist-mediated improvements in hepatic insulin sensitivity?

  2005cited by this paper
• Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity?

  2005cited by this paper
• Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans.

  2003cited by this paper
• ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism.

  2002cited by this paper
• Effect of losartan on plasma C-reactive protein in type 2 diabetic patients with microabluminuria.

  2002cited by this paper
• Diet-induced insulin resistance in mice lacking adiponectin/ACRP30

  2002cited by this paper
• The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

  2001cited by this paper
• The hormone resistin links obesity to diabetes

  2001cited by this paper
• The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

  2001cited by this paper
• Oświadczenie w sprawie konfliktu interesów

  2001cited by this paper
• Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy.

  2000cited by this paper
• Atrial flutter in grown-up congenital heart (GUCH) patients. Clinical characteristics of affected population.

  2000cited by this paper
• Clinical efficacy of an automated high-sensitivity C-reactive protein assay.

  1999cited by this paper
• A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies.

  1994cited by this paper
• A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies.

  1993cited by this paper
• Insulin resistance in essential hypertension.

  1987cited by this paper
• Glucose clamp technique: a method for quantifying insulin secretion and resistance.

  1979cited by this paper
• Statistical Principles in Experimental Design

  1963cited by this paper

• From Adipose Tissue to Endothelial Cells—Pleiotropic Role of Vaspin in Pathogenesis of Metabolic and Cardiovascular Diseases

  2025cites this paper
• Aortic Remodeling in Patients with Arterial Hypertension: Pathophysiological Mechanisms, Therapeutic Interventions and Preventive Strategies—A Position Paper from the Heart and Hypertension Working Group of the Italian Society of Hypertension

  2025cites this paper
• Visfatin and Subclinical Atherosclerosis in Type 2 Diabetes: Impact of Cardiovascular Drugs

  2023cites this paper
• The relationship between adipose tissue RAAS activity and the risk factors of prediabetes: a systematic review and meta-analysis

  2023cites this paper
• Biomarkers In Hypertension And Hypertension-Related Disorders.

  2022cites this paper
• Leukocyte subtypes, gelatinases, and their tissue inhibitors in a group of subjects with asymptomatic carotid atherosclerosis

  2022cites this paper
• Effects of physical exercise combined with captopril or losartan on left ventricular hypertrophy of hypertensive rats

  2021cites this paper
• Oxidative stress and vascular stiffness in hypertension: A renewed interest for antioxidant therapies?

  2019cites this paper
• Chronological renal resistive index increases related to atherosclerotic factors, and effect of renin-angiotensin system inhibitors

  2018cites this paper
• Matrix metalloproteinase in the cardiovascular remodeling of hypertension: current insights and therapeutic potential

  2018cites this paper
• Study of serum visfatin level in patients with nonalcoholic fatty liver disease and its role in progression to nonalcoholic steatohepatitis

  2018cites this paper
• Increased plasma RBP4 concentration in older hypertensives is related to the decreased kidney function and the number of antihypertensive drugs-results from the PolSenior substudy.

  2017cites this paper
• Matrix metalloproteinase-2 -735C/T polymorphism is associated with resistant hypertension in a specialized outpatient clinic in Brazil.

  2017cites this paper
• Blood pressure-lowering agents response : a systematic review and genome wide study

  2017cites this paper
• Matrix Metalloproteases in Arterial Hypertension and their Trend after Antihypertensive Treatment

  2017cites this paper
• Caveolin 1 Modulates Aldosterone‐Mediated Pathways of Glucose and Lipid Homeostasis

  2016cites this paper
• Changes in activities of circulating MMP-2 and MMP-9 in patients suffering from heart failure in relation to gender, hypertension and treatment: a cross-sectional study.

  2016cites this paper
• Decreased immunoreactivity of visfatin in the pancreas and liver of rats with renovascular hypertension.

  2016cites this paper
• Increased Circulating Tissue Inhibitor of Metalloproteinase‐2 Is Associated With Resistant Hypertension

  2016cites this paper
• Relationship between Cystatin C, Retinol-binding Protein 4 and Framingham Risk Score in Healthy Postmenopausal Women.

  2016cites this paper
• Retinol-Binding Protein 4 Induces Cardiomyocyte Hypertrophy by Activating TLR4/MyD88 Pathway.

  2016cites this paper
• Increased Circulating Visfatin Is Associated With Progression of Kidney Disease in Non-Diabetic Hypertensive Patients.

  2016cites this paper
• Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus

  2015cites this paper
• Associations Between Inflammation and Cognitive Function in African Americans and European Americans

  2015cites this paper
• The effects of canrenone on inflammatory markers in patients with metabolic syndrome

  2015cites this paper
• Retinol-binding protein 4 in obese and obese-diabetic postmenopausal women in Montenegro

  2015cites this paper
• Serum retinol-binding protein 4 levels are elevated but do not contribute to insulin resistance in newly diagnosed Chinese hypertensive patients

  2014cites this paper
• Associations Between Inflammation and Cognitive Function in African Americans and European Americans

  2014cites this paper
• Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.

  2014cites this paper
• Visfatin is not associated with inflammatory markers in patients on hemodialysis.

  2014cites this paper
• Angiotensin II receptor blockade and insulin sensitivity in overweight and obese adults with elevated blood pressure

  2013cites this paper
• Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.

  2013cites this paper
• The Effect of Sodium Restricted Diet on Plasma Visfatin Levels in Hypertensive Patients with Visceral Obesity

  2013cites this paper
• Circulating matrix metalloproteinases and their inhibitors in hypertension.

  2012cites this paper
• Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients

  2012cites this paper
• The Effects of Antihypertensive Agents in Metabolic Syndrome – Benefits Beyond Blood Pressure Control

  2012cites this paper
• Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis

  2012cites this paper
• Comprehensive Evaluation of the Effects of Enalapril on Matrix Metalloproteinases Levels in Hypertension

  2012cites this paper
• MMP-2 and sTNF-R1 Variability in Patients with Essential Hypertension: 1-Year Follow-Up Study

  2012cites this paper
• Original article Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study

  2012cites this paper
• Inhibition of Gelatinase B (Matrix Metalloprotease-9) Activity Reduces Cellular Inflammation and Restores Function of Transplanted Pancreatic Islets

  2012cites this paper
• Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study

  2012cites this paper
• Short-term antihypertensive therapy lowers the C-reactive protein level.

  2012cites this paper
• Inflammation in hypertension: current therapeutic approaches.

  2011cites this paper
• Comparison of the effects of losartan vs. ramipril on several adipocytokines and vascular remodeling biomarkers

  2011cites this paper
• Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study

  2011cites this paper
• CARDIOVASCULAR OUTCOMES IN PATIENTS WITH COMORBID HYPERTENSION AND DIABETES TREATED WITH ACE INHIBITORS VERSUS ARBS: A POPULATION-BASED OBSERVATIONAL ANALYSIS

  year unknowncites this paper
• O R I G I N a L I N V E S T I G a T I O N Open Access

  year unknowncites this paper